Search

Your search keyword '"Robinson, Murray"' showing total 178 results

Search Constraints

Start Over You searched for: Author "Robinson, Murray" Remove constraint Author: "Robinson, Murray"
178 results on '"Robinson, Murray"'

Search Results

7. The burden of Legionnaires' disease in New Zealand (LegiNZ): a national surveillance study

8. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells

9. Data from De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model

10. Supplementary Figure 1, Table 1 from De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model

12. A Mammalian Telomerase-Associated Protein

23. Young people's Perception of Group Climate in Juvenile Justice Centers in an Australian State, a Pilot Study.

27. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells

34. Abstract A5: Tivozanib, a selective VEGFR TKI, potently blocks angiogenesis and growth in tumors that express a high level of VEGF-C and are refractory to VEGF-A blockade.

35. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress

36. Abstract 5063: Preclinical evaluation of an EMT multi-gene biomarker index for predicting response to inhibitors of EGFR and IGF1R

37. Abstract 1631: Tumorigenicity of IGF-1R and IR: Rationale for co-targeting IGF-1R and IR in cancer

38. Abstract 1727: Preclinical evaluation of pan-VEGFR inhibitor tivozanib in combination with capecitabine, sirolimus or erlotinib in genetically engineered tumor models support combinations based on complementary mechanisms

40. Abstract 3267: Human population based engineered breast tumor model for in vivo biomarker discovery

46. Abstract B18: Variation in response to VEGFR inhibitor tivozanib in a unique population‐based tumor model enables the development of a multigene response biomarker

47. Abstract A233: Generation ofin vitroandin vivotumor models driven by insulin‐like growth factor receptor (IGF1R) and their use in the development of OSI‐906, a selective IGF1R inhibitor

50. De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model

Catalog

Books, media, physical & digital resources